Compare ELUT & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | NNVC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 35.2M |
| IPO Year | 2020 | 2008 |
| Metric | ELUT | NNVC |
|---|---|---|
| Price | $0.93 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 279.0K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | 10.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,293,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.85 |
| 52 Week High | $1.51 | $2.23 |
| Indicator | ELUT | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 25.99 |
| Support Level | $0.84 | $1.10 |
| Resistance Level | $1.04 | $1.29 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.88 | 8.62 |
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.